According to Tianjin Pharmaceutical's announcement, the cumulative deviation value of the company's stock closing price increase reached 20% for two consecutive trading days on September 28 and September 29, 2026, which is an abnormal fluctuation in stock trading. After self-inspection and written inquiries to the controlling shareholders and indirect controlling shareholders, as of the date of disclosure of the announcement, the company and controlling shareholders had no important matters that should have been disclosed but not disclosed. Shanghai Shangshi and Shangshi Investment intend to sell 100% of their total shares in Shanghai Liuliguang. The relevant state-owned shares were publicly listed on September 24, 2026, and there are currently no intended transferees. The company achieved operating income of 1,313 billion yuan for the first half year of 2026, a year-on-year decrease of 17.33%; net profit to mother was 43.173,500 yuan, a year-on-year decrease of 12.43%; net profit after deducting non-return to mother was 42.881 million yuan, a year-on-year decrease of 63.24%. Investors are kindly requested to be aware of investment risks.

According to Tianjin Pharmaceutical's announcement, the cumulative deviation value of the company's stock closing price increase reached 20% for two consecutive trading days on September 28 and September 29, 2026, which is an abnormal fluctuation in stock trading. After self-inspection and written inquiries to the controlling shareholders and indirect controlling shareholders, as of the disclosure date of the announcement, the company and controlling shareholders had no important matters that should have been disclosed but not disclosed. Shanghai Shangshi and Shangshi Investment intend to sell 100% of their total shares in Shanghai Liuliguang. The relevant state-owned shares were publicly listed on September 24, 2026, and there are currently no intended transferees. The company achieved operating income of 1,313 billion yuan for the first half year of 2026, a year-on-year decrease of 17.33%; net profit to mother was 43.173,500 yuan, a year-on-year decrease of 12.43%; net profit after deducting non-return to mother was 42.881 million yuan, a year-on-year decrease of 63.24%. Investors are kindly requested to be aware of investment risks.